ArticleThe Lancet regional health. Western Pacific2022
Prevalence and risk of atrial fibrillation in China: A national cross-sectional epidemiological study.
Article in The Lancet regional health. Western Pacific, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 4 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Bidirectional association between COPD and AF: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- Screening for Atrial Fibrillation in Stroke Prevention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Reviews in cardiovascular medicine · 2025Pooled it
- 2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): Executive Summary.Thrombosis and haemostasis · 2024Guideline
- Pooled it
- Clinical efficacy and mechanistic study of fulvning granules in symptomatic atrial fibrillation: a randomized controlled trial with untargeted metabolomics analysis.Frontiers in pharmacology · 2026Trial
- A single-dose, four-cycle, fully repetitive crossover bioequivalence of dabigatran etexilate in Chinese.BMC pharmacology & toxicology · 2025Trial
- Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial.European heart journal · 2024Trial
- Effectiveness of a Mindfulness Meditation App Based on an Electroencephalography-Based Brain-Computer Interface in Radiofrequency Catheter Ablation for Patients With Atrial Fibrillation: Pilot Randomized Controlled Trial.JMIR mHealth and uHealth · 2023Trial
- Effect of Left Atrial Appendage Closure on Cardiac Function.Journal of cardiovascular development and disease · 2026Article
- Disparities in anticoagulation therapy for older adults with non-valvular atrial fibrillation: a comparative study of urban and suburban communities.BMC geriatrics · 2026Article
- Atrial Fibrillation and Great Saphenous Vein Insufficiency: Exploration of Common Pathways in Hemodynamic Derangements and Systemic Inflammation.Reviews in cardiovascular medicine · 2026Review
- Article
- Quantitative detection of left atrial fibrosis in patients with atrial fibrillation: a comparative study of two 3D whole-heart late gadolinium enhancement sequences.The international journal of cardiovascular imaging · 2026Article
- Development and Validation of a Coronary Computed Tomography Angiography-Based Radiomics-Integrated Model for Noninvasive Detection of Left Atrial Appendage Thrombus in Atrial Fibrillation.Journal of the American Heart Association · 2026Article
- Comparison between automated electronic blood pressure monitor and electrocardiography in atrial fibrillation screen.Journal of geriatric cardiology : JGC · 2026Article
- Article
- RT-3DE TEE combined with 2D-STI to evaluate the correlation between left atrial and left auricular function and stroke in patients with non-valvular atrial fibrillation: a clinical investigation.BMC cardiovascular disorders · 2026Article
- A case of post-ablation chest pain: Navigating the diagnostic dilemma.Heart rhythm O2 · 2026Article
- Changing patterns of the burden for atrial fibrillation/atrial flutter attributable to high systolic blood pressure in China from 1990 to 2021.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Temporal trends of atrial fibrillation and atrial flutter burden across the BRICS: An observational study analysis for the GBD 2021.Medicine · 2026Observational
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 20 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is the most common persistent cardiac arrhythmia. This study aimed to estimate its prevalence and explore associated factors in adults aged 18 years or older in China. Methods: Study data were derived from a national sample from July 2020 to September 2021. Participants were recruited using a multistage stratified sampling method from twenty-two provinces, autonomous regions, and municipalities in China. AF was determined based on a history of diagnosed AF or electrocardiogram results. Findings: A total of 114,039 respondents were included in the final analysis with a mean age of 55 years (standard deviation 17), 52·1% of whom were women. The crude prevalence of AF was 2·3% (95% confidence interval [CI] 1·7-2·8) and increased with age. The age-standardized AF prevalence was 1·6% (95% CI 1·6-1·7%) overall, and 1·7% (1·6-1·8%), 1·4% (1·3-1·5%), 1·6% (95% CI 1·5-1·7%), and 1·7% (1·6-1·9%) in men, women, urban areas, and rural areas, respectively. The prevalence was higher in the central regions (2·5%, 2·3-2·7%) than in the western regions (1·5%, 1·0-2·0%) and eastern regions (1·1%, 1·0-1·2%) in the overall population, either in the gender or residency subgroups. The associated factors for AF included age (per 10 years; odds ratio 1·41 [95% CI 1·38-1·46]; Interpretation: The prevalence of AF was 1.6% in the Chinese adult population and increased with age, with significant geographic variation. Older age, male sex, and cardiovascular disease were potent factors associated with AF. It is crucial to increase the awareness of AF and disseminate standardized treatment in clinical settings to reduce the disease burden. Funding: This research was supported the Nature Science Foundation of Hubei province (No: 2017CFB204).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.